bluebird bio (BLUE) PT Lowered to $31 at BMO Capital

February 24, 2021 9:01 AM EST Send to a Friend
BMO Capital analyst Matthew Luchini lowered the price target on bluebird bio (NASDAQ: BLUE) to $31.00 (from $36.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login